Allogeneic Transplantation From Related Haploidentical Donors

Leukemia Clinical Trial

Official title:

Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00185692
• Other study ID #: IRB-13371
• Secondary ID: 75117BMT124
• Status: Completed
• Phase: Phase 2
• Start date: August 2000
• Est. completion date: December 2010

Study information

• Verified date: January 2015
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).

Description:

An alternative to conventional allogeneic bone marrow transplantation is by using a non-myeloablative conditioning regimen. This regime would consist of both; total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG). Used in combination to achieve engraftment of haploidentical CD34+ selected peripheral blood stem cells in older patients or patients with underlying medical conditions that preclude standard allogeneic treatment. The expected results of this transplant regime will be expected to result in hematopoietic and immunologic reconstitution, decreased deaths related to the treatment regimen and decreased gravft-vs-host disease (GVHD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months and older

Eligibility

Inclusion Criteria:

• Age = 50 years with hematologic malignancies treatable by a mixed chimera allogeneic HCT.

• For patients = 50 years of age with hematologic malignacies treatable with mixed chimera HCT who because of pre-exisiting medical conditions or prior therapy are considered to be at high risk for regimen-related toxicity associated with conventional transplants.

• Indolent advanced stage NHL, CLL, HD - Must have received and failed front-line therapy.

• Multiple myeloma (Stage II or III) - Must have received prior chemotherapy. Consolidation after prior autografting is permitted.

• AML/ALL - Must be in complete hematologic remission and have received cytotoxic chemotherapy at some stage before transplant. Patients with molecular or cytogenetic relapse will be accepted providing a donor is available. Patients with persistent or refractory disease will be considered on a case by case basis and transplants must be approved by the principal investigator.

• CML - Patients will be accepted in chronic or accelerated phase. Patients who have received prior autografts after high dose therapy or have undergone intensive chemotherapy for either peripheral blood stem cell mobilization or treatment of advanced CML may be enrolled provided they are in CR, chronic phase or accelerated phase.

• MDS - All patients with MDS will be eligible for this protocol, however, those patients with >10% blasts will require chemotherapy to reduce the blast % to < 10%.

• SAA - Patients with severe aplastic anemia who have failed front line therapy.

• A fully HLA-identical sibling donor is not available.

• A matched unrelated donor has not been identified.

• A haploidentical related donor is available who is in good health and does not have contraindications to donation.

Exclusion Criteria:

• Patients with rapidly progressive intermediate or high grade NHL

• Uncontrolled CNS involvement with disease

• Fertile men

• Women unwilling to use contraceptive techniques during and for 12 months following treatment

• Females who are pregnant

• Cardiac function: ejection fraction < 30% or cardiac failure requiring therapy

• Pulmonary: DLCO < 40% predicted and/or receiving supplementary continuous oxygen

• Liver function abnormalities: elevation of bilirubin to > 4 mg/dl and/or transaminases > 3x the upper limit of normal. If hyperbilirubinemai is due to a known cause that will not increase the risks of transplant, than this upper limit may be exceeded.

• Renal: creatinine clearance < 50 cc/min (24 hour urine collection)

• Karnofsky performance score < 60%

• Patients with poorly controlled hypertension.

• Documented fungal disease that persists despite treatment

• HIV positive patients.

• Hepatitis B and C positive patients will be evaluated on a case by case basis

• Psychiatric disorders or psychosocial problems which in the opinion of the primary physician or principal investigator would place the patient at unacceptable risk from this regimen.

Related Conditions & MeSH terms

• Blood Cancer
• CLL
• Graft Versus Host Disease
• Graft vs Host Disease
• Hodgkin Disease
• Hodgkin's Disease
• Leukemia
• Malignancy
• MDS
• Neoplasms
• NHL

Intervention

Procedure:
• non-myeloablative hematopoietic cell transplantation
TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.

Drug:
• Anti-Thymocyte Globulin
1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
• Cyclosporine
6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
• Mycophenolate Mofetil
15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
• G-CSF
16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
• Solumedrol
1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
• Acetaminophen
650 mg PO, 30 minutes prior to infusion Pain reliever
• Diphenydramine
50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
• Hydrocortisone
100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and Antithymocyte Globulin Transplant Conditioning	number achieving donor cell engraftment (>95%) by day 90 after transplant.	100 days
Secondary	Acute Graft-versus-Host Disease (GVHD) Grade 2-4 Risk From Time of Transplant Until Day 90 Post-transplant	GVHD grading system goes from 0-4 where grade 4 is the most severe. Grade 0 and 1 do not require systemic treatment, Grade 2-4 require treatment. This trial evaluated the risk of developing acute GVHD grades 2-4 within 90 days of transplant.	90 days